Fifteen Scientific Studies with 22nd Century’s Reduced Nicotine SPECTRUM® Cigarettes Presented at the Society for Research...
March 10 2016 - 11:13AM
Business Wire
22nd Century Group, Inc. (NYSE MKT: XXII), a plant
biotechnology company that is a leader in tobacco harm reduction,
announced today that the initial results of an unprecedented number
– more than fifteen – independent scientific studies involving the
Company’s SPECTRUM® reduced nicotine tobacco cigarettes were
presented by independent scientific researchers at the 22nd Annual
Meeting of the Society for Research on Nicotine & Tobacco
(“SRNT”) held on March 2 – 5, 2016, in Chicago, Illinois. The
annual event was highly attended by participants from around the
world, including acclaimed university scientists, FDA and other
regulators, and industry professionals. The initial results of the
independent scientific studies involving the Company’s proprietary
reduced nicotine tobacco cigarettes adds to the mounting body of
evidence which shows that the Company’s Very Low Nicotine
cigarettes reduce cigarette consumption and assist in smoking
cessation.
Due to the fact that the results presented at the SRNT
Conference are preliminary and not yet published, 22nd Century is
not yet able to release or cite specific study data; however, this
link from the SRNT.org website is to the summaries of the initial
results of all the scientific studies that were presented at the
SRNT Annual Meeting, including the studies on the Company’s reduced
nicotine tobacco (see abstract numbers: SYM1B, PA17-1, PA22-5,
POS1-19, POS1-50, POS1-74, POS1-104, POS1-107, POS1-129, POS1-137,
POS1-146, POS1-148, PA8-5, POS2-6, POS4-20, POS4-95).
“There is a mounting body of evidence that demonstrates that
22nd Century’s proprietary Very Low Nicotine cigarettes are a
highly useful tool in helping smokers to quit smoking with no
withdrawal symptoms and no exposure to new toxicants,” explained
Dr. Paul Rushton, 22nd Century’s Vice President of Plant
Biotechnology. “As a result of the numerous independent trials that
have already been conducted, we believe a national nicotine
reduction policy would have broad beneficial effects on health in
the U.S.”
Henry Sicignano, III, President and Chief Executive Officer of
22nd Century Group, stated “We are very proud of our mission – to
reduce the harm caused by smoking – and we are honored to have so
many prestigious independent researchers conducting important
studies with our proprietary Very Low Nicotine tobacco. We look
forward to working with interested researchers around the world to
design and provide the exact types of Very Low Nicotine research
cigarettes that they desire to fit their independent research
plans. Ultimately, we hope to be able to provide our highly
effective and exciting products to consumers in the U.S. as soon as
permitted by the appropriate regulators.”
About 22nd Century Group, Inc.
22nd Century is a plant biotechnology company focused on
technology which allows it to increase or decrease the level of
nicotine in tobacco plants and the level of cannabinoids in
cannabis plants through genetic engineering and plant breeding. The
Company’s primary mission is to reduce the harm caused by smoking.
22nd Century currently owns or exclusively controls more than 200
issued patents and more than 50 pending patent applications around
the world. The Company’s strong IP position led to a licensing
agreement with British American Tobacco (“BAT”), the world’s second
largest tobacco company. Visit www.xxiicentury.com for more
information.
Cautionary Note Regarding Forward-Looking Statements: This press
release contains forward-looking information, including all
statements that are not statements of historical fact regarding the
intent, belief or current expectations of 22nd Century Group, Inc.,
its directors or its officers with respect to the contents of this
press release, including but not limited to our future revenue
expectations. The words “may,” “would,” “will,” “expect,”
“estimate,” “anticipate,” “believe,” “intend” and similar
expressions and variations thereof are intended to identify
forward-looking statements. We cannot guarantee future results,
levels of activity or performance. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should
be considered with any written or oral forward-looking statements
that we may issue in the future. Except as required by applicable
law, including the securities laws of the United States, we do not
intend to update any of the forward-looking statements to conform
these statements to reflect actual results, later events or
circumstances, or to reflect the occurrence of unanticipated
events. You should carefully review and consider the various
disclosures made by us in our annual report on Form 10-K for the
fiscal year ended December 31, 2015, filed on February 18, 2016,
including the section entitled “Risk Factors,” and our other
reports filed with the U.S Securities and Exchange Commission which
attempt to advise interested parties of the risks and factors that
may affect our business, financial condition, results of operation
and cash flows. If one or more of these risks or uncertainties
materialize, or if the underlying assumptions prove incorrect, our
actual results may vary materially from those expected or
projected.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160310006023/en/
Investor Relations:IRTH CommunicationsAndrew Haag,
866-976-4784xxii@irthcommunications.comorRedington, Inc.Tom
Redington, 203-222-7399
22nd Century (AMEX:XXII)
Historical Stock Chart
From Apr 2024 to May 2024
22nd Century (AMEX:XXII)
Historical Stock Chart
From May 2023 to May 2024